Unique ID issued by UMIN | UMIN000005329 |
---|---|
Receipt number | R000006331 |
Scientific Title | A randomized clinical trial of personalized peptide vaccination with oral low-dose metronomic cyclophosphamide for metastatic castration-resistant prostate cancer (CRPC) |
Date of disclosure of the study information | 2011/04/01 |
Last modified on | 2019/12/06 15:50:27 |
A randomized clinical trial of personalized peptide vaccination with oral low-dose metronomic cyclophosphamide for metastatic castration-resistant prostate cancer (CRPC)
Personalized peptide vaccination with metronomic cyclophosphamide for metastatic CRPC
A randomized clinical trial of personalized peptide vaccination with oral low-dose metronomic cyclophosphamide for metastatic castration-resistant prostate cancer (CRPC)
Personalized peptide vaccination with metronomic cyclophosphamide for metastatic CRPC
Japan |
Castration-resistant prostate cancer
Urology |
Malignancy
NO
To investigate ability of oral metronomic cyclophosphamide with personalized peptide vaccination to deplete immuno-suppression cells in metastatic CRPC patients
Safety,Efficacy
Exploratory
Pragmatic
Phase II
Evaluation of ability of oral metronomic cyclophosphamide with personalized peptide vaccination to deplete immuno-suppression cells.
1. Evaluation of long-term prognosis (progression free survival and overall survival).
2. Adverse effects of peptide vaccination / The safety of the protocol is evaluated based on the NCI-CTC.
3. Evaluation of immunological responses (cytotoxic T lymphocytes [CTL]and anti-peptide IgG) before and after peptide vaccination.
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
Institution is not considered as adjustment factor.
Central registration
2
Treatment
Medicine |
A: Personalized peptide vaccination with oral metronomic cyclophosphamide treatment
Select peptide candidates (up to 4), to which peptide-specific IgGs are detected before vaccination, and administer peptides (maximum 4) that showed the highest reactivity. Emulate these peptides individually and subcutaneously inject them separately (3.0 mg/1.5-3.0 ml/peptide) every 1 week interval. Start oral use of cyclophosphamide 1T (1X) (50 mg/day, 50 days) on the same day with peptide vaccination. 1st treatment: total 8 times, every weeks)
After the first cycle of 8 vaccinations, the peptides were re-selected according to the titers of peptide-specific IgG at every cycle of 8 vaccinations and administered at 2, 3, or 4 week intervals until unacceptable toxicity or withdrawal of consent.
B: Personalized peptide vaccine alone
Select peptide candidates (up to 4), to which peptide-specific IgGs are detected before vaccination, and administer peptides (maximum 4) that showed the highest reactivity. Emulate these peptides individually and subcutaneously inject them separately (3.0 mg/1.5-3.0 ml/peptide) every 1 week interval. After the first cycle of 8 vaccinations, the peptides were re-selected according to the titers of peptide-specific IgG at every cycle of 8 vaccinations and administered at 2, 3, or 4 week intervals until unacceptable toxicity or withdrawal of consent.
20 | years-old | <= |
Not applicable |
Male
The subjects must satisfy the following conditions.
1) Patients must be diagnosed as prostate cancer pathologically at the initial treatment. The patients must be suffering from metastatic castration-resistant prostate cancer after standard treatment.
2) Patients must be positive for HLA-A2, HLA-A24 or HLA-A3 super type.
3) Patients must have IgG reactive to at least two of 31 peptide candidates.
4) Patients must be at a score level
of 0-1 of performance status (PS) (ECOG).
5) Patients must be expected to survive more than 3 months.
6) Patients must satisfy the followings:
WBC > 2,500/mm3
Lymphocyte > 1,000/mm3
Hb > 8.0g/dl
Platelet > 100,000/mm3
Serum Creatinine < 2.5 x upper limit of normal
Total Bilirubin < 2 x upper limit of normal
7) Patients must be more 20 year-old.
8) Written informed consent must be obtained from patients.
The following patients must be excluded:
1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation).
2) Patients with the past history of severe allergic reactions.
3) Patients who are judged inappropriate for the clinical trial by doctors.
60
1st name | Masanori |
Middle name | |
Last name | Noguchi |
Kurume University School of Medicine
Research Center for Innovative Cancer Therapy, Division of Clinical Research Department of Urology
830-0011
Asahi-machi 67, Kurume, Japan
0942-31-7989
noguchi@med.kurume-u.ac.jp
1st name | Akira |
Middle name | |
Last name | Yamada |
Kurume University School of Medicine
Research Center for Innovative Cancer Therapy, Cancer Vaccine Department Division
830-0011
Asahi-machi 67, Kurume, Japan
0942-31-7572
akiymd@med.kurume-u.ac.jp
Kurume University School of medicine, Department of Immunology and immunotherapy
The Ministry of Education, Culture, Sports, Science, and Technology, Japan
Japanese Governmental office
Japan
Kurume University
Kurume University School of Medicine
67 Asahi-machi, Kurume, Japan
0942-35-3311
sangaku@kurume-u.ac.jp
NO
久留米大学病院 (福岡県) Kurume University Hospital
2011 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2011 | Year | 03 | Month | 28 | Day |
2011 | Year | 03 | Month | 28 | Day |
2011 | Year | 04 | Month | 01 | Day |
2015 | Year | 03 | Month | 31 | Day |
2011 | Year | 03 | Month | 28 | Day |
2019 | Year | 12 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006331
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |